develop
nanoparticl
drug
deliveri
progress
leap
bound
last
decad
facilit
possibl
effi
caciou
therapi
fatal
diseas
develop
stem
either
unsuit
physicochem
characterist
exist
drug
molecul
limit
solubl
henc
poor
bioavail
inadequaci
convent
deliveri
system
provid
safe
effi
cient
deliveri
chapter
focus
precis
need
develop
novel
nanoparticul
drug
carrier
reason
popular
drug
deliveri
scientist
text
also
discuss
variou
strategi
includ
differ
formul
target
approach
adopt
overcom
challeng
present
inher
properti
drug
molecul
exampl
nanoparticul
drug
deliveri
system
alreadi
gain
market
approv
cite
discuss
wherev
applic
plethora
vari
nanodrug
deliveri
system
academ
institut
also
industri
organ
led
avail
huge
databas
compris
sever
research
paper
patent
world
describ
new
dosag
form
numer
fund
agenc
industri
activ
promot
research
nanoparticul
drug
deliveri
vehicl
huge
invest
made
end
divers
concurr
effort
creat
awar
immens
potenti
new
drug
deliveri
system
look
upon
therapeut
regimen
futur
mani
reason
behind
develop
success
nanoparticul
drug
deliveri
system
year
ago
entir
attent
pharmaceut
industri
focus
novel
develop
design
variou
dosag
form
primarili
due
expiri
exist
patent
surfeit
poorli
solubl
drug
candid
problem
nonspecifi
citi
convent
dosag
form
circumst
develop
nanoparticul
drug
deliveri
system
gain
huge
momentum
due
number
divers
factor
list
follow
section
chapter
pharmaceut
industri
pois
provid
qualiti
product
patient
time
increas
maintain
profi
tabil
howev
process
demand
extens
scientifi
c
innov
fi
nancial
support
develop
new
chemic
entiti
transit
laboratori
market
requir
compani
expend
high
million
us
dollar
apart
huge
invest
develop
new
drug
also
extens
time
consum
process
limit
success
rate
research
progress
drug
discoveri
area
result
develop
variou
poorli
solubl
drug
candid
solubl
limit
drug
candid
turn
lead
poor
bioavail
lower
therapeut
effi
caci
situat
formul
therapeut
molecul
nanoparticul
deliveri
system
observ
improv
bioavail
henc
elicit
desir
therapeut
effect
candid
nanoparticl
also
receiv
promin
due
probabl
benefi
ts
like
biodegrad
biocompat
high
encapsul
characterist
probabl
surfac
function
nanoparticl
found
exhibit
sever
advantag
parenter
drug
deliveri
counter
aggreg
phenomenon
commonli
observ
microparticl
smaller
size
nanoparticl
endow
better
distribut
profi
le
system
owe
small
size
nanoparticl
found
effect
travers
mani
biolog
barrier
signifi
cant
import
abil
permeat
blood
brain
barrier
bbb
although
brain
administr
effect
rout
treatment
variou
brain
diseas
sever
limit
due
highli
imperm
natur
bbb
potenti
cross
barrier
numer
public
demonstr
effect
nanoparticl
target
variou
central
nervou
system
disord
nanospectra
bioscienc
texa
usa
recent
initi
clinic
trial
nanoparticl
base
nanoshel
treatment
brain
tumor
size
nanoparticl
offer
distinct
advantag
compar
convent
dosag
form
tunabl
size
system
greatli
infl
uenc
releas
profi
le
encapsul
activ
compon
formul
could
thu
control
drug
releas
site
action
nanoparticl
found
highli
versatil
system
encapsul
deliveri
chemic
drug
moieti
also
nuclic
acid
therapeut
dna
sirna
imag
diagnost
agent
sitespecifi
c
deliveri
detect
variou
ligand
attach
surfac
nanoparticl
guid
specifi
c
locat
within
bodi
thu
nanoparticul
drug
carrier
found
applic
sever
divers
quarter
drug
deliveri
research
due
tunabl
properti
foreseen
futur
pharmaceut
biotechnolog
industri
drug
transport
biolog
barrier
larg
depend
upon
solubl
solubl
exhibit
import
infl
uenc
drug
permeat
absorpt
solubl
drug
concern
formul
scientist
diffi
culti
develop
oral
parenter
deliveri
system
poorli
solubl
drug
though
pharmaceut
sector
wit
vast
advanc
drug
discoveri
therapeut
horizon
expand
exist
drug
molecul
novel
drug
candid
pose
major
solubl
problem
variou
report
indic
approxim
drug
current
market
poor
water
solubl
onethird
drug
candid
pharmacopoeia
exhibit
solubl
limit
low
water
solubl
turn
hamper
adequ
absorpt
henc
lead
low
therapeut
effi
caci
solubl
constraint
drug
novel
drug
candid
thu
one
major
obstacl
develop
therapeut
effect
drug
deliveri
system
nanoparticl
made
naturalsynthet
polym
lipid
protein
phospholipid
receiv
greater
attent
due
higher
stabil
opportun
surfac
modifi
cation
tailor
achiev
control
drug
releas
diseasespecifi
c
local
either
tune
materi
characterist
alter
surfac
chemistri
establish
nanocarri
becom
concentr
preferenti
tumor
mass
site
infl
ammat
site
infect
virtu
enhanc
permeabl
retent
epr
effect
vasculatur
accumul
target
site
hydrophob
biodegrad
polymer
nanoparticl
act
local
drug
depot
depend
upon
makeup
carrier
thu
provid
reservoir
continu
suppli
encapsul
therapeut
compound
diseas
site
solid
tumor
system
gener
use
provid
target
cellulartissu
deliveri
drug
improv
oral
bioavail
sustain
druggen
effect
target
tissu
solubil
drug
intravascular
deliveri
improv
stabil
therapeut
agent
enzymat
degrad
nucleas
proteas
especi
relev
protein
peptid
nucleotid
base
agent
thu
advantag
use
nanoparticl
drug
deliveri
result
two
main
basic
properti
small
size
use
biodegrad
materi
mani
studi
demonstr
nanoparticl
submicron
size
number
advantag
convent
dosag
form
drug
deliveri
carrier
advantag
convent
drug
deliveri
system
better
suitabl
intraven
iv
deliveri
smallest
capillari
bodi
diamet
therefor
size
particl
distribut
bloodstream
must
signifi
cantli
smaller
without
form
aggreg
ensur
particl
lead
embol
addit
type
cell
permit
uptak
submicron
particl
larger
counterpart
gener
nanoparticl
rel
higher
intracellular
uptak
compar
microparticl
avail
much
wider
rang
biolog
target
due
small
size
rel
mobil
desai
et
al
found
nm
nanoparticl
fold
greater
uptak
microparticl
fold
greater
uptak
microparticl
caco
cell
line
secondli
use
biodegrad
materi
nanoparticl
prepar
allow
sustain
drug
releas
within
target
site
period
day
even
week
regard
materi
formul
biodegrad
nanoparticl
formul
polym
lipid
develop
intracellular
sustain
drug
deliveri
especi
drug
intracellular
target
rapid
escap
nanoparticl
endolysosom
compart
cytoplasm
compart
demonstr
addit
demonstr
effect
sustain
intracellular
drug
level
thu
allow
effi
cient
interact
cytoplasm
receptor
thu
nanoparticl
could
serv
effect
deliveri
vehicl
drug
cytoplasm
target
summar
nanoparticl
proven
advantag
convent
dosag
form
offer
reliabl
altern
pharmaceut
industri
improv
therapeut
effect
exist
drug
elicit
better
effect
new
chemic
entiti
deliv
sensit
molecul
like
protein
peptid
dna
rna
nanoemuls
optic
isotrop
thermodynam
stabl
system
two
immisc
liquid
typic
water
oil
surfact
one
liquid
dispers
droplet
anoth
liquid
emuls
nanoscop
droplet
size
typic
rang
nm
often
refer
nanoemuls
nanoemuls
offer
enhanc
solubil
capac
poorli
solubl
drug
increas
drug
load
turn
lead
higher
bioavail
formul
therapeut
moieti
variou
gra
gener
regard
safe
approv
satur
unsatur
fatti
acid
nonion
surfact
commonli
use
formul
nanoemuls
formul
nanoemuls
either
involv
appropri
energi
input
ultrason
high
pressur
homogen
microfl
uidiz
may
spontan
process
commerci
product
like
estrasorb
flexogan
base
nanoemuls
technolog
estrasorb
estradiol
topic
emuls
develop
novavax
recommend
reduct
vasomotor
symptom
menopaus
women
estrasorb
compos
soyabean
oil
water
polysorb
water
base
micellar
nanoparticl
technolog
technolog
prove
poorli
water
solubl
molecul
like
estradiol
success
formul
commerci
use
nanoparticul
deliveri
vehicl
yet
anoth
exampl
nanoemuls
base
product
flexogan
develop
alpharx
canada
pain
relief
cream
base
colloid
dispers
nanoparticl
oil
droplet
contain
natur
pain
medica
like
menthol
camphor
nanoparticl
permeat
faster
skin
therebi
provid
rapid
relief
case
nanoparticul
deliveri
respons
higher
bioavail
quicker
onset
action
encapsul
activ
bioavail
poorli
water
solubl
drug
frequent
relat
particl
size
drug
molecul
particl
size
reduct
drug
molecul
improv
overal
surfac
area
dissolut
properti
thu
lead
higher
bioavail
drug
formul
drug
nanocryst
one
success
strategi
improv
drug
solubl
bioavail
numer
method
may
employ
gener
drug
nanocryst
includ
high
pressur
homogen
media
mill
nanoprecipit
highpressur
homogen
involv
passag
coars
drug
suspens
along
suitabl
stabil
tini
homogen
gap
high
pressur
bar
process
perform
presenc
water
nonaqu
media
nonaqu
medium
specifi
calli
use
chanc
drug
degrad
aqueou
media
pressur
respons
gener
nanoparticl
due
variou
principl
cavit
disintegr
shear
base
upon
three
import
technolog
design
nanocryst
product
use
highpressur
homogen
technolog
piston
gap
homogen
water
dissocub
technolog
microfl
uidiz
technolog
technolog
nanopur
technolog
triglid
fi
rst
clinic
approv
nanocryst
product
develop
use
highpressur
homogen
indic
treatment
hypercholesterolemia
triglid
produc
use
technolog
skyepharma
market
sciel
pharma
inc
drug
candid
product
fenofi
brate
lipophil
compound
practic
insolubl
water
bioavail
fenofi
brate
sever
limit
due
poor
water
solubl
although
clinic
observ
reveal
higher
bioavail
fedstat
patient
attribut
lipid
associ
compound
meal
enhanc
solubl
henc
absorpt
anoth
studi
micron
fenofi
brate
found
enhanc
dissolut
henc
oral
bioavail
studi
also
confi
rmed
reason
nanocryst
fenofi
brate
still
lower
particl
size
improv
bioavail
compar
micron
form
homogen
method
media
mill
success
produc
drug
nanocryst
primarili
due
simplic
scalabl
addit
media
mill
also
econom
compar
methodolog
nanoparticl
gener
depend
upon
shear
forc
impact
move
bed
mill
materi
mixtur
drug
stabil
despit
limit
method
like
drug
loss
adhes
still
prefer
pharmaceut
industri
gener
drug
nanoparticl
rapamun
one
fi
rst
nanocryst
product
develop
use
media
mill
technolog
elan
drug
technolog
rapamun
consist
sirolimu
poorli
water
solubl
compound
indic
prophylaxi
organ
reject
patient
receiv
renal
transplant
elan
term
technolog
nanocryst
technolog
involv
particl
size
reduct
drug
formul
drug
nanoparticl
particl
size
reduct
lead
higher
dissolut
higher
absorpt
henc
enhanc
bioavail
rapamun
found
overcom
problem
associ
rapamycin
convent
dosag
form
sirolimu
demonstr
bioavail
improv
patient
complianc
better
shelflif
compar
convent
product
addit
product
also
met
tremend
econom
success
emend
anoth
success
product
merck
develop
elan
drug
technolog
aprepit
activ
ingredi
emend
poor
aqueou
solubl
gml
moder
permeabl
caco
permeabl
report
cm
convent
formul
aprepit
observ
food
play
signifi
cant
role
rate
amount
drug
absorb
emend
hand
elimin
requir
drug
absorpt
bioavail
enhanc
compar
convent
product
product
also
recent
approv
japan
avail
us
europ
japan
variou
product
like
tricor
fenofi
brate
megac
es
megestrol
invega
sustenna
xeplion
paliperidon
palmit
also
produc
nanoparticl
media
mill
overcom
solubl
issu
detail
product
list
tabl
two
method
describ
topdown
approach
particl
size
reduct
aim
enhanc
solubl
bioavail
drug
candid
method
rel
simpl
econom
howev
process
possess
complex
formul
sensit
molecul
respect
size
surfac
control
case
bottomup
approach
provid
altern
challeng
method
gener
drug
nanoparticl
approach
specifi
calli
use
need
load
nanoparticl
mani
activ
ingredi
surfac
nanoparticl
need
function
alter
base
approach
nanoprecipit
method
involv
gener
drug
nanoparticl
nucleat
growth
drug
crystal
nucleat
process
trigger
dissolv
excess
drug
suitabl
solvent
result
supersatur
solut
supersatur
mixtur
normal
ad
antisolventstabil
mixtur
produc
nanocryst
variou
paramet
process
control
ultim
size
surfac
characterist
nanocryst
produc
nanoprecipit
method
present
preclin
stage
date
system
yet
met
clinic
industri
success
though
pharmaceut
industri
wit
enorm
develop
fi
eld
nanoparticul
drug
deliveri
system
still
face
numer
scientifi
c
queri
challeng
limit
solubl
poor
bioavail
allow
pharmaceut
industri
look
beyond
convent
drug
deliveri
system
primari
reason
nanodrug
deliveri
system
occupi
signifi
cant
posit
formul
research
develop
develop
technolog
limit
pharmaceut
industri
contin
widerang
accept
nanoparticl
base
drug
deliveri
system
still
far
realiz
develop
nanoparticul
drug
deliveri
system
need
investig
uniqu
pharmacolog
action
safeti
profi
le
drug
releas
profi
le
vitroin
vivo
ivivc
correl
pharmacokinet
pharmacodyanam
profi
le
need
thoroughli
establish
routin
adopt
clinic
applic
one
major
drawback
associ
convent
drug
deliveri
system
nonspecifi
c
natur
convent
dosag
form
gener
formul
use
excess
drug
compar
actual
dose
formul
deliv
small
fraction
drug
affect
area
major
part
distribut
throughout
bodi
random
distribut
lead
unwant
side
effect
toxic
nanoparticl
abl
provid
site
specifi
citi
target
specifi
c
tissu
organ
bodi
give
desir
therapeut
effect
minim
side
effect
target
capac
nanoparticl
one
import
reason
behind
success
target
drug
deliveri
proven
highli
benefi
cial
treatment
cancer
sinc
major
anticanc
drug
normal
known
harm
noncancer
bodi
cell
drug
target
nanoparticl
usual
achiev
surfac
function
variou
ligand
identifi
bind
certain
cellular
receptor
bodi
target
drug
deliveri
broad
terminolog
investig
decad
specifi
calli
cancer
research
also
extend
organ
suscept
sitespecifi
c
diseas
follow
section
chapter
dedic
numer
facet
target
drug
deliveri
target
drug
deliveri
normal
achiev
either
via
activ
target
passiv
target
activ
target
involv
direct
rout
drug
andor
deliveri
system
diseas
biolog
site
minim
side
effect
rna
interfer
rnai
therapi
monoclon
antibodi
well
known
exampl
approach
rnai
approach
rapidli
expand
fi
eld
particularli
gain
momentum
due
huge
invest
pharmaceut
industri
develop
rnai
base
therapeut
therapi
potenti
treatment
variou
fatal
diseas
like
cancer
viral
infect
variou
genet
diseas
detail
rnai
therapi
describ
chapter
book
hand
monoclon
antibodybas
therapi
investig
variou
diseas
cardiovascular
disord
infl
ammatori
disord
cancer
antibodi
bind
specifi
c
cell
intend
target
stimul
immunolog
respons
target
cell
passiv
target
may
achiev
employ
drug
deliveri
system
administ
via
differ
deliveri
rout
deliveri
system
enhanc
effect
drug
util
function
target
site
exampl
drug
deliveri
enhanc
permeabl
cancer
tissu
compar
normal
counterpart
due
leaki
vasculatur
enhanc
permeat
retent
epr
effect
former
similarli
deliveri
nasal
transderm
intrauterin
rout
also
util
passiv
target
target
deliveri
cancer
one
mostinvestig
area
major
commerci
product
belong
categori
convent
cancer
therapi
ie
chemotherapi
radiotherapi
effect
earli
stage
cancer
detect
howev
advers
effect
aris
therapi
pose
major
challeng
nanoparticlebas
target
drug
deliveri
provid
huge
potenti
cancer
therapi
primarili
due
favor
dimens
surfac
function
carrier
system
system
enter
tumor
cell
interact
cellular
receptor
thu
abl
inhibit
growth
spread
cancer
target
nanocarri
cancer
facilit
precis
cellular
molecular
alter
henc
effect
less
harm
normal
cell
convent
treatment
includ
chemotherapi
radiotherapi
tabl
cite
nanoparticul
system
along
respect
oncolog
indic
develop
variou
industri
major
nanoparticul
system
target
drug
deliveri
cancer
surfac
function
appropri
ligand
ligand
facilit
cellular
bind
intern
specifi
c
therapeut
effect
optim
process
attach
ligand
nanoparticul
surfac
one
chief
factor
govern
precis
target
nanoparticl
anoth
import
factor
includ
exclus
target
ligand
cancer
cell
neglig
occurr
healthi
cell
bodi
common
target
strategi
list
tabl
past
decad
wit
sharp
rise
number
target
drug
nanoparticl
approv
cancer
therapi
liposom
nanoparticl
fi
rst
categori
success
allevi
advers
effect
associ
drug
convent
dosag
form
excel
exampl
liposom
doxorubicin
result
signifi
cant
reduct
sever
cardiotox
nativ
drug
doxil
pegyl
liposom
doxorubicin
fi
rst
nanoparticul
product
approv
target
cancer
therapi
pegyl
liposom
demonstr
improv
pharmacokinet
pharacodynam
profi
le
polyethyeleneglycol
peg
coat
thu
constitut
one
fi
rst
commerci
target
strategi
also
afford
addit
stabil
nanoparticl
prevent
elimin
reticuloendothili
system
re
tag
peg
nanoparticl
surfac
also
known
steric
stabil
stealth
effect
also
report
improv
blood
circul
time
uptak
macrophag
abraxan
anoth
commerci
success
product
target
cancer
therapi
abraxan
paclitaxel
proteinbound
particl
inject
suspens
albuminbound
form
paclitaxel
mean
particl
size
approxim
nm
paclitaxel
indic
target
cancer
therapi
use
nanoparticl
breast
cancer
therapi
poorli
solubl
molecul
mani
formul
challeng
associ
paclitaxel
like
inher
solubl
problem
toxic
issu
moreov
exist
formul
taxol
drug
exhibit
sever
advers
effect
attribut
excipi
cremophor
el
compar
taxol
abraxan
provid
improv
tumor
cell
penetr
paclitaxel
decreas
occurr
cremophor
relat
advers
effect
benefi
ts
abraxan
due
natur
properti
key
ingredi
albumin
transport
lipophil
molecul
noncoval
bind
albumin
predomin
plasma
protein
bind
glycoprotein
receptor
maintain
transendotheli
oncot
pressur
gradient
regul
transport
boundunbound
plasma
compon
fatti
acid
steroid
thyroxin
amino
acid
receptor
subsequ
bind
success
format
caveola
key
determin
transcellular
endotheli
permeabl
albumin
accumul
breast
lung
head
neck
prostat
cancer
bind
secret
protein
acid
rich
cystein
sparc
sparcalbumin
interact
support
accumul
albumin
tumor
increas
effect
albuminbound
paclitaxel
nabpaclitaxel
success
nab
nanoparticl
pave
way
use
differ
type
cancer
larg
number
clinic
trial
util
nanoparticl
present
progress
drug
develop
treatment
central
nervou
system
cn
disord
increas
howev
preclin
clinic
success
still
far
realiti
global
market
drug
central
nervou
system
cn
diseas
limit
due
variou
reason
like
high
cost
drug
develop
high
risk
benefi
ratio
limit
understand
diseas
formul
intricaci
brain
deliveri
diffi
culti
effi
cientli
treat
cn
disord
includ
limit
number
avail
drug
lack
broad
understand
etiolog
brain
diseas
exampl
diseas
categori
see
figur
includ
alzheim
diseas
huntington
diseas
parkinson
diseas
amyotroph
later
sclerosi
hiv
infect
brain
brain
tumor
howev
past
year
tremend
improv
drug
discoveri
cn
diseas
accord
report
pharmaceut
research
manufactur
america
phrma
approxim
divers
drug
variou
cn
disord
overview
market
progress
cn
drug
develop
data
base
press
inform
releas
respect
pharmaceut
compani
till
juli
majorli
addict
depress
current
research
product
pipelin
addit
tuft
center
studi
drug
develop
state
approxim
drug
develop
variou
cn
disord
like
multipl
sclerosi
epilepsi
howev
physicochem
characterist
molecul
unfavor
effi
cient
transport
blood
brain
barrier
bbb
one
diffi
cult
biolog
barrier
hinder
provis
effect
strategi
treat
cn
diseas
bbb
consist
differ
cellular
compon
endotheli
cell
pericyt
astrocyt
microgli
cell
interconnect
tight
imperm
junction
presenc
natur
barrier
drug
deliveri
cn
may
perform
use
invas
method
noninvas
method
combin
invas
method
gener
variou
complic
thu
adopt
case
fatal
diseas
noninvas
categori
nanoparticul
drug
carrier
demonstr
great
potenti
success
therapi
surfac
modifi
cation
system
allow
direct
specifi
c
receptor
brain
small
size
exploit
travers
bbb
addit
nanoparticl
also
prevent
structur
modifi
cation
drug
deliv
drug
desir
site
origin
form
properti
nanoparticl
like
biodegrad
low
particl
size
nm
prolong
circul
surfac
modifi
cation
receptor
medic
transcytosi
largescal
product
abil
possibl
load
drugspeptid
abil
control
releas
encapsul
activ
agent
make
ideal
target
drug
deliveri
brain
tabl
indic
variou
target
strategi
brain
target
use
nanoparticl
immens
market
opportun
colon
target
drug
product
estim
us
market
product
colorect
cancer
reach
million
compound
annual
growth
rate
cagr
colon
target
drug
deliveri
steadili
grown
treatment
variou
colon
specifi
c
diseas
well
system
deliveri
macromolecul
peptid
target
colon
becom
import
treat
diseas
like
infl
ammatori
bowel
diseas
crohn
diseas
colon
cancer
ulcer
coliti
research
group
specifi
calli
investig
effi
caci
polymer
nanoparticl
colon
cancer
well
ulcer
coliti
exampl
braintarget
nanoparticl
preclin
stage
modifi
ed
nanoparticl
colon
target
formul
use
natur
synthet
polym
wide
rang
polym
establish
investig
colon
target
potenti
colon
target
nanoparticl
demonstr
abil
enhanc
solubl
absorpt
bioavail
encapsul
drug
addit
colon
target
nanoparticl
also
shown
huge
potenti
deliv
peptid
etiolog
variou
colon
diseas
shown
macrophag
activ
cours
diseas
cascad
immun
respons
infl
ame
cellular
structur
colon
activ
macrophag
effi
cientli
take
nanoparticl
govern
accumul
larg
number
nanoparticl
colon
region
accumul
turn
elicit
pronounc
therapeut
effect
colon
target
nanosystem
literatur
report
describ
employ
nanoparticl
colon
target
deliveri
variou
encapsul
moieti
zheng
et
al
report
incorpor
thymopentin
potent
immunomodul
drug
phsensit
chitosan
nanoparticl
coat
eudragit
improv
stabil
oral
bioavail
encapsul
agent
uniform
nanoparticl
size
nm
moder
high
encapsul
around
formul
nanoparticl
found
effect
protect
encapsul
moieti
enzymat
degrad
prolong
degrad
halftim
result
lymphocyt
prolifer
test
vivo
evalu
rat
demonstr
nanoparticl
could
use
effect
vector
oral
deliveri
thymopentin
wang
et
al
report
develop
cyclosporin
cya
load
phsensit
nanoparticl
es
variou
vivo
studi
conduct
research
group
reveal
nanoparticl
increas
absorpt
cya
could
attribut
fast
stomach
empt
rate
site
specifi
c
absorpt
lower
degrad
rate
entrap
moieti
lumin
content
high
bioadhes
nanoparticl
intestin
mucosa
author
claim
investig
could
help
design
dosag
form
peptid
protein
drug
research
report
effi
cienci
es
nanoparticl
favor
vehicl
select
absorpt
drug
gut
administ
oral
rout
prove
encapsul
rhodamin
rho
model
agent
nanoparticl
evalu
rho
releas
profi
le
distribut
adhes
transit
rat
gut
observ
nanoparticl
decreas
distribut
adhes
rho
stomach
increas
valu
intestin
addit
nanocarri
report
control
drug
releas
site
releas
rate
gi
tract
scientist
also
investig
potenti
es
improv
oral
deliveri
proteas
inhibitor
dog
incorpor
proteas
inhibitor
hiv
cgp
es
nanoparticl
found
substanti
increas
oral
bioavail
compound
administr
dog
achiev
plasma
level
compar
obtain
studi
conduct
lower
anim
mice
lung
present
promis
rout
drug
deliveri
due
noninvas
natur
possibl
system
local
drug
deliveri
pulmonari
market
expect
increas
billion
cagr
grow
need
novel
therapeut
system
treatment
respiratori
diseas
like
tuberculosi
pulmonari
hypertens
cystic
fi
brosi
asthma
chronic
obstruct
pulmonari
diseas
copd
sever
acut
respiratori
syndrom
sar
pulmonari
rout
also
increasingli
exploit
deliveri
peptid
vaccin
view
enorm
need
nanoparticl
provid
right
therapeut
option
treatment
varieti
respiratori
diseas
nanoparticl
system
target
pulmonari
drug
deliveri
offer
variou
advantag
uniform
distribut
drug
alveoli
bypass
fi
rst
pass
metabol
high
solubl
sustain
releas
properti
reduc
side
effect
deliveri
macromolecul
improv
patient
complianc
lung
target
use
nanoparticl
also
achiev
parenter
rout
howev
research
prefer
pulmonari
rout
latter
summari
variou
nanoparticul
carrier
intend
target
lung
present
tabl
thu
evid
nanoparticul
drug
carrier
cater
distinct
need
play
defi
nite
role
overcom
lag
encount
convent
drug
deliveri
system
numer
type
fascin
nanoparticul
drug
carrier
stem
research
conduct
last
three
decad
also
notabl
number
condit
may
appli
via
differ
administr
rout
better
therapeut
outcom
persist
academia
industri
system
success
accomplish
cumbersom
transit
laboratori
clinic
book
intend
provid
overview
differ
therapeut
nanoparticl
challeng
exampl
nanoparticul
carrier
target
lung
modifi
ed
amphotericin
b
phospholipid
apolipoprotein
lung
infect
amilorid
hydrochlorid
liposom
cystic
fi
brosi
secretori
leukocyt
proteas
inhibitor
liposom
cystic
fi
brosi
antisens
oligodeoxynucleotid
polymer
nanoparticl
asthma
vasoact
intestin
peptid
protamin
nanoparticl
asthma
indomethacin
ketoprofen
solid
lipid
nanoparticl
asthma
antisens
oligonucleotid
plga
nanoparticl
lung
cancer
leuprolid
liposom
lung
cancer
hlaa
tcell
epitop
mycobacterium
tuberculosi
chitosan
nanoparticl
tuberculosi
plasmid
encod
antigen
tuberculosi
plgapei
nanoparticl
tuberculosi
insulin
plga
plgapei
pei
chitosan
algin
diabet
encount
transit
clinic
set
solut
may
adopt
surmount
challeng
success
stori
drug
deliveri
nanoparticl
